Assessing Guselkumab Efficacy in Treating Pityriasis Rubra Pilaris
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on May 8th, 2024
|
Pityriasis rubra pilaris is a rare inflammatory condition that shares similar immunological pathways with psoriasis such as interleukin-23 overexpression and T-helper 17 activation. Psoriasis can be treated with guselkumab, an antibody that can bind to IL-23p19, and the pharmaceutical company Janssen had sponsored a study to assess its efficacy to treat pityriasis rubra pilaris.
The study included 4 females and 8 males who had been diagnosed with pityriasis rubra pilaris via histology with an average of 82.6% of the body surface area being affected. The mean Psoriasis Area Severity Index (PASI) score of the participants was 30.6 and the mean Dermatology Life Quality Index (DLQI) score was 20.1. The participants were treated with a subcutaneous injection containing 100 mg of guselkumab after enrollment, at the 4th, 12th, and 20th week of the study. Upon completion, the researchers concluded that the usage of guselkumab reduced the PASI score by 61.8% and DLQI score by 60.2%, which translates to a reduction of severity and improvement in life quality. Assessment at the 36th week of the study showed continued clinical improvement indicating a sustainability of the treatment. These promising data warrant additional research with a larger sample size and a more heterogeneous population.
The study included 4 females and 8 males who had been diagnosed with pityriasis rubra pilaris via histology with an average of 82.6% of the body surface area being affected. The mean Psoriasis Area Severity Index (PASI) score of the participants was 30.6 and the mean Dermatology Life Quality Index (DLQI) score was 20.1. The participants were treated with a subcutaneous injection containing 100 mg of guselkumab after enrollment, at the 4th, 12th, and 20th week of the study. Upon completion, the researchers concluded that the usage of guselkumab reduced the PASI score by 61.8% and DLQI score by 60.2%, which translates to a reduction of severity and improvement in life quality. Assessment at the 36th week of the study showed continued clinical improvement indicating a sustainability of the treatment. These promising data warrant additional research with a larger sample size and a more heterogeneous population.